Predictive Modeling of In Vivo Response to Gemcitabine in Pancreatic Cancer

Abstract

A clear contradiction exists between cytotoxic in-vitro studies demonstrating effectiveness of Gemcitabine to curtail pancreatic cancer and in-vivo studies failing to show Gemcitabine as an effective treatment. The outcome of chemotherapy in metastatic stages, where surgery is no longer viable, shows a 5-year survival <5%. It is apparent that in-vitro… (More)
DOI: 10.1371/journal.pcbi.1003231

Topics

5 Figures and Tables

Cite this paper

@inproceedings{Lee2013PredictiveMO, title={Predictive Modeling of In Vivo Response to Gemcitabine in Pancreatic Cancer}, author={James J. Lee and Justin Huang and Christopher G. England and Lacey R. McNally and Hermann B. Frieboes}, booktitle={PLoS Computational Biology}, year={2013} }